10.1016/j.ccr.2007.08.004 Cancer Cell
Compounded semaglutide, when prepared by an FDA-registered 503B outsourcing facility, contains the identical active ingredient and can cost $150$350/month a fraction of brand pricing
Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
The Benefits Men Are Seeing When asking Is GLP-1 medication effective for men, its important to look beyond just the number on the scale
Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors